Seer is a Redwood City proteomics toolmaker whose cash pile now exceeds the entire equity value, and the second-quarter print makes that gap harder to ignore. Scientific validation of the Proteograph platform keeps compounding in journals and at conferences, yet product and service demand still cannot clear last year's bar. The investment debate is no longer whether the nanoparticle workflow works in expert hands. It is whether that science converts into recurring kit and service revenue before the treasury is the only asset left to argue about.
Revenue slipped to $3.1 million as academic funding caution and longer commercial evaluations stretched the sales cycle. Sequential growth from the first quarter and a rebound in consumable pull-through give the new commercial chief something to point to. Gross margin held near half of sales while operating spend still dwarfs the top line. Cash, cash equivalents, and investments ended June at $209.5 million, well above the mid-September equity value. The market is not confused about the science. It is pricing a high probability that the cash gets spent on a business that remains subscale.
Management reaffirmed a full-year revenue band that implies a sharp second-half recovery after a first half that ran well behind last year. Independent Nature Genetics work and a Korea University cancer-screening presentation at ASMS keep the scientific flywheel spinning, and a late-September HUPO session is slated to show PRECISE-SG100K data. Meanwhile the board has rejected a string of cash-plus-CVR bids from the Radoff-JEC group and from the chair himself. The next several months decide whether Proteograph adoption finally shows up in orders, or whether the cash discount keeps widening as another year of almost-flat guidance burns through the treasury.